Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

EntreMed announces financial results for the third quarter of 2009

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported results for the three- and nine-month periods ending September 30, 2009.

16 Nov 2009

PAF receives additional funding support for serving patients with multiple myeloma

Patient Advocate Foundation (PAF) -- a national non-profit organization that seeks to safeguard patients through effective mediation assuring access to care, maintenance of employment and preservation of their financial stability relative to their diagnosis of life threatening or debilitating diseases -- is pleased to announce that it has received additional funding support for serving patients with multiple myeloma through its Co-Pay Relief Program (CPR).

13 Nov 2009

Senesco's multiple myeloma drug candidate data to be presented at the AACR-NCI-EORTC conference

Senesco Technologies, Inc. announced today that Catherine Taylor, one of the Company's funded researchers, will be presenting pre-clinical stability and biological activity data on SNS-01, Senesco's multiple myeloma drug candidate, at the 2009 American Association for Cancer Research (AACR)-National Cancer Institute (NCI)-European Organization for Research and Treatment of Cancer (EORTC) Molecular Targets and Cancer Therapeutics Conference.

12 Nov 2009

Keryx Biopharmaceuticals to present KRX-0401 Phase 1/2 clinical trial data at the ASH meeting

Keryx Biopharmaceuticals, Inc. today announced that data from its Phase 1/2 clinical trial of KRX-0401 (perifosine) in combination with bortezomib (+/- dexamethasone) has been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009.

12 Nov 2009

Aeterna Zentaris reports consolidated revenues of $8.6 million for third quarter 2009

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results as at and for the three-month and nine-month periods ended September 30, 2009.

11 Nov 2009

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Onyx Pharmaceuticals, Inc. today announced nearly 20 presentations evaluating carfilzomib and ONX 0803 (SB 1518) in hematological cancers at the 51st American Society of Hematology (ASH) Annual Meeting December 5-8, 2009 in New Orleans, LA. Among the data presentations are four oral and seven poster presentations highlighting data from the carfilzomib development program in patients with relapsed and refractory multiple myeloma.

11 Nov 2009

Allos Therapeutics awards NCCN a grant to evaluate pralatrexate

NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding.

11 Nov 2009

Scientific article supports AEterna Zentaris' development of perifosine inhibitor

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced publication of a scientific article in the renowned Journal of Urology, supporting the development of the Company's PI3K/Akt pathway inhibitor oral compound, perifosine, for the treatment of cancer.

9 Nov 2009

Clinical Data announces financial results for its second fiscal quarter ended September 30, 2009

Clinical Data, Inc. today announced the Company’s operational and financial results for its second fiscal quarter ended September 30, 2009.

9 Nov 2009

TREANDA induces durable responses in indolent B-cell non-Hodgkin's lymphoma patients

Cephalon, Inc. today announced the journal Cancer has published a pivotal study demonstrating that TREANDA® (bendamustine HCl) for Injection induced durable responses in patients with indolent B-cell non-Hodgkin's lymphoma (NHL) whose disease had progressed during or within six months of treatment with rituximab.

6 Nov 2009

Bortezomib lymphoma drug may be effective against bone cancer in children and teens: Study

A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer.

5 Nov 2009

EntreMed to present its Aurora A/angiogenic kinase inhibitor data at the AACR-NCI-EORTC conference

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced presentations for its Aurora A/angiogenic kinase inhibitor, ENMD-2076, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held November 15-19, 2009 in Boston, Massachusetts. Presentations are listed below.

3 Nov 2009

NOXXON Pharma commences human dosing in Spiegelmer NOX-A12 clinical trial

NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, announced today the successful initial dosing of healthy volunteers in a first-in-human clinical trial with Spiegelmer® NOX-A12. NOX-A12 is NOXXON’s second drug candidate entering the clinical stage of development within only five months.

2 Nov 2009

Seminar on multiple myeloma

MediCom Worldwide, Inc., an accredited provider of continuing medical education for physicians, pharmacists, and nurses, announces a Friday Satellite Symposium on Multiple Myeloma Preceding the 51st ASH Annual Meeting entitled Unifying Practice Patterns Among Academic and Community Clinicians: Focus on Myeloma.

29 Oct 2009

NCI awards UAMS Myeloma Institute $19.5M grant

The internationally known multiple myeloma program at the University of Arkansas for Medical Sciences (UAMS) will receive $19.5 million over five years to continue work that has already developed new treatments for this cancer of plasma cells, a type of white blood cell present in the bone marrow.

28 Oct 2009

MMRF raises over $1.8 million at its 13th annual Fall Gala

The Multiple Myeloma Research Foundation (MMRF) raised over $1.8 million at its 13th annual Fall Gala held on Saturday evening in Greenwich, Conn. Funds raised at this premier fundraising event, attended by more than 1,000 guests, will support the MMRF’s efforts to accelerate the development of the next generation of treatments for patients with multiple myeloma, a rare and incurable blood cancer, and to find a cure for the disease.

28 Oct 2009

ImmunoCellular Therapeutics presents additional data from its ICT-107 Phase I clinical trial

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is focused on the development of novel immune-based cancer therapies, today announced additional data from its Phase I clinical trial evaluating ICT-107, the Company’s dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme (GBM).

27 Oct 2009

ImmunoCellular Therapeutics to present Phase I clinical trial data of ICT-107 vaccine in New Orleans

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, today announced that it will be presenting today, at the Annual Meeting of the Congress of Neurological Surgeons in New Orleans, Louisiana at 3:15pm central time, data from its Phase I clinical trial investigating the role that its ICT-107 vaccine may play in increasing patient survival and inhibiting tumor progression in patients with glioblastoma, the most common and most aggressive type of primary brain tumor.

26 Oct 2009

Seattle Genetics reports its third-quarter financial results

Seattle Genetics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. The company also highlighted recent product development progress.

24 Oct 2009

Celgene announces fiscal 2009 third-quarter results

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $259.8 million, or non-GAAP earnings per diluted share of $0.56 for the quarter ended September 30, 2009. Non-GAAP net income for the third quarter of 2008 was $185.9 million, or non-GAAP earnings per diluted share of $0.40.

22 Oct 2009

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

EntreMed announces financial results for the third quarter of 2009

PAF receives additional funding support for serving patients with multiple myeloma

Senesco's multiple myeloma drug candidate data to be presented at the AACR-NCI-EORTC conference

Keryx Biopharmaceuticals to present KRX-0401 Phase 1/2 clinical trial data at the ASH meeting

Aeterna Zentaris reports consolidated revenues of $8.6 million for third quarter 2009

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Allos Therapeutics awards NCCN a grant to evaluate pralatrexate

Scientific article supports AEterna Zentaris' development of perifosine inhibitor

Clinical Data announces financial results for its second fiscal quarter ended September 30, 2009

TREANDA induces durable responses in indolent B-cell non-Hodgkin's lymphoma patients

Bortezomib lymphoma drug may be effective against bone cancer in children and teens: Study

EntreMed to present its Aurora A/angiogenic kinase inhibitor data at the AACR-NCI-EORTC conference

NOXXON Pharma commences human dosing in Spiegelmer NOX-A12 clinical trial

Seminar on multiple myeloma

NCI awards UAMS Myeloma Institute $19.5M grant

MMRF raises over $1.8 million at its 13th annual Fall Gala

ImmunoCellular Therapeutics presents additional data from its ICT-107 Phase I clinical trial

ImmunoCellular Therapeutics to present Phase I clinical trial data of ICT-107 vaccine in New Orleans

Seattle Genetics reports its third-quarter financial results

Celgene announces fiscal 2009 third-quarter results

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in